Myeloma specialist at Mayo Clinic, Dr. Angela Dispenzieri, has been tinkering with using dead measles virus to help fight multiple myeloma. I have written about it a number of times. At first the research didn't seem to be coming together. But lately I've heard Angela and her team have started figuring out the dosing and
The internet is flooded with excitement following the FDA's limited approval of celgene's newest IMiD, pomalidomide (trade name, POMALYST). POM is an analogue of thalidomide (trade name, Thalomid). Researchers actually developed POM before Revlimid, but sat on it for a decade--choosing to intensify clinical study activity recently, culminating in yesterday's FDA approval. I'm going to
More about measles virus clinical trial: Could myeloma cells be killed so fast it might endanger patients?
Yesterday I re-visited the topic of a new anti-myeloma therapy Mayo Clinic researchers are investigating. My post focused on a Phase 1 study my friend, Mike, just joined called MCo38C, “A Phase 1 Trial of Systemic Administration of (Edmonston Strain) of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide in Patients with
I need to delay my ASH coverage of the trade exhibits until later this week. Today I wanted to share some exciting news with you. A good myeloma friend of mine from the Menominee area in western Wisconsin, Mike, starts his first day today as part of a long awaited Mayo Clinic trial. Let me